SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
T2 Biosystems, Inc. (TTOO) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+2499900%).
- Analyst consensus target $5.00 (+2499900% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 25/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TTOO
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-19.19
Book Value / Share$0.00
Revenue / Share$2.76
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$5.00 (+2499900%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$-361.85 |
$119K |
$-31.39M |
-26378.2% |
| 2015 |
$-220.91 |
$2.81M |
$-45.29M |
-1610% |
| 2016 |
$-210.66 |
$4.08M |
$-54.8M |
-1343.2% |
| 2017 |
$-194.29 |
$4.67M |
$-62.43M |
-1337.9% |
| 2018 |
$-126.12 |
$10.5M |
$-51.15M |
-487.2% |
| 2019 |
$-6,934.20 |
$8.34M |
$-63.11M |
-757.2% |
| 2020 |
$-2,027.86 |
$18.13M |
$-49.21M |
-271.4% |
| 2021 |
$-1,683.72 |
$28.06M |
$-53.5M |
-190.7% |
| 2022 |
$-1,242.48 |
$22.31M |
$-63.37M |
-284.1% |
| 2023 |
$-19.19 |
$7.19M |
$-50.08M |
-696.2% |
